[go: up one dir, main page]

AR070936A1 - 1,2,4 -triazoles trisustituidos - Google Patents

1,2,4 -triazoles trisustituidos

Info

Publication number
AR070936A1
AR070936A1 ARP090100970A ARP090100970A AR070936A1 AR 070936 A1 AR070936 A1 AR 070936A1 AR P090100970 A ARP090100970 A AR P090100970A AR P090100970 A ARP090100970 A AR P090100970A AR 070936 A1 AR070936 A1 AR 070936A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
hydrogen
alkyloxy
halo
Prior art date
Application number
ARP090100970A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR070936A1 publication Critical patent/AR070936A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a procesos para su preparacion; composiciones farmacéuticas que contienen dichos compuestos; y su uso en tratamientos, de acuerdo con la formula (1). Se refiere, en particular, a potentes moduladores alostéricos positivos de receptores de acetilcolina nicotínicos, donde dichos moduladores alostéricos positivos tienen la capacidad de incrementar la eficacia de agonistas de receptores nicotínicos. Reivindicacion 1: Un compuesto de acuerdo con la formula (1) o una de sus formas estereoisomeras, donde: R1 es fenilo no sustituido; benzodioxan-6-ilo no sustituido; piridinilo no sustituido; o fenilo o piridinilo sustituido con 1, 2 o 3 sustituyentes seleccionados del grupo que consiste en halo, trifluorometilo, trifluorometoxi, alquilo C1-3, alquiloxi C1-3, alquiloxi C1-3-alquilo C1-3, alquilamino C1-3, cicloalquilo C3-6, cicloalquiloxi C3-6, cicloalquilamino C3-6, cicloalquilo C3-6-alquilo C1-3, cicloalquilo C3-6-alquiloxi C1-3, y cicloalquilo C3-6-alquilamino C1-3; R2 es hidrogeno, halo, alquilo C1-3, alquiloxi C1-3 o trifluorometoxi; R3 es hidrogeno, halo, o trifluorometilo; R4 es hidrogeno, o halo; R2 y R3 pueden formar un radical -OCF2-O-; Alk es alcanodiilo C1-6 o alquenodiilo C2-6 recto o ramificado; R5 es hidrogeno, hidroxi, alquiloxi C1-3, halo, R6R7N-C(=O)- o R8-O-C(=O)-; R6 es alquilo C1-3, cicloalquilo C3-6 o cicloalquilo C3-6-alquilo C1-3; R7 es hidrogeno o alquilo C1-3; o R6 y R7 forman pirrolidinilo o piperidinilo, donde cada uno está opcionalmente sustituido con hidroxilo; R8 es hidrogeno o alquilo C1-4; o una sal de adicion aceptable para uso farmacéutico, o un hidrato o un solvato de dicho compuesto.
ARP090100970A 2008-03-19 2009-03-18 1,2,4 -triazoles trisustituidos AR070936A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08152987 2008-03-19

Publications (1)

Publication Number Publication Date
AR070936A1 true AR070936A1 (es) 2010-05-12

Family

ID=39670401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100970A AR070936A1 (es) 2008-03-19 2009-03-18 1,2,4 -triazoles trisustituidos

Country Status (21)

Country Link
US (1) US8778974B2 (es)
EP (1) EP2257535B1 (es)
JP (1) JP5383788B2 (es)
KR (1) KR101564303B1 (es)
CN (1) CN102066343B (es)
AR (1) AR070936A1 (es)
AU (1) AU2009226988B2 (es)
CA (1) CA2714662C (es)
CL (1) CL2009000662A1 (es)
EA (1) EA018186B1 (es)
ES (1) ES2442932T3 (es)
IL (1) IL208181A (es)
MX (1) MX2010010127A (es)
MY (1) MY152486A (es)
NZ (1) NZ587669A (es)
PE (1) PE20091618A1 (es)
TW (1) TWI433847B (es)
UA (1) UA102681C2 (es)
UY (1) UY31721A1 (es)
WO (1) WO2009115547A1 (es)
ZA (1) ZA201006690B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
WO2009050186A1 (en) * 2007-10-18 2009-04-23 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
CL2009001125A1 (es) * 2008-05-09 2011-02-11 Janssen Pharmaceutica Nv Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
WO2012104782A1 (en) 2011-02-03 2012-08-09 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
MA34957B1 (fr) 2011-02-23 2014-03-01 Lupin Ltd Derives heteroaryle a titre modulateurs des nachr alpha 7
EA022164B1 (ru) 2011-02-25 2015-11-30 Янссен Фармацевтика Нв (ПИРИДИН-4-ИЛ)БЕНЗИЛАМИДЫ КАК АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ АЛЬФА 7 nAChR
JP2014509641A (ja) 2011-03-31 2014-04-21 ルピン・リミテッド アルツハイマー病やパーキンソン病などの神経変性疾患の治療に用いられるニコチン性アセチルコリン受容体モジュレータとしてのピロール誘導体
ES2606043T3 (es) 2011-07-05 2017-03-17 Lupin Limited Derivados de biarilo como moduladores de nAChR
EP2822946A1 (en) 2012-03-06 2015-01-14 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
US20150259344A1 (en) * 2012-10-02 2015-09-17 Dainippon Sumitomo Pharma Co., Ltd. Imidazole derivative
US20150299178A1 (en) 2012-11-12 2015-10-22 Lupin Limited Thiazole Derivatives as Alpha 7 NACHR Modulators
EP2945941B1 (en) 2013-01-16 2016-12-07 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
WO2014141091A1 (en) 2013-03-13 2014-09-18 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
EP3010899A1 (en) 2013-06-17 2016-04-27 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
US11136312B2 (en) 2017-05-12 2021-10-05 Board of Trustees of the Southern Illinois University 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
US11912687B2 (en) 2017-05-12 2024-02-27 Board of Trustees of the Southern Illinois University 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
CN118930491B (zh) * 2024-07-26 2025-04-18 西北师范大学 一种3-氟烷基-5-氨基-1,2,4-三氮唑类化合物的合成方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795907A (fr) * 1972-02-25 1973-06-18 Luso Farmaco Inst 2-amino-4-arylthiazoles 5-substitues et leur preparation
EP0248523B1 (en) 1986-05-07 1991-10-16 FISONS plc Pyrazoles
JPS6339868A (ja) 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
US4761422A (en) 1986-11-20 1988-08-02 Lusofarmaco Istituto Lusofarmaco D'italia Spa (2-amino-4-aryl-thiazole-5-yl)ethanols and their derivatives having diuretic activity and methods for preparing the same
CA2195847A1 (en) 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
KR970705560A (ko) 1995-08-02 1997-10-09 호아껭 우리아치 토렐로 항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity)
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
EP0946528B1 (en) 1996-12-23 2003-04-09 Bristol-Myers Squibb Pharma Company OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
AU9648098A (en) 1997-10-27 1999-05-17 Takeda Chemical Industries Ltd. Adenosine a3 receptor antagonists
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2211420T3 (es) 1999-07-21 2004-07-16 F. Hoffmann-La Roche Ag Derivados de triazol.
EP1205478A4 (en) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
FR2802530B1 (fr) * 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
CA2397661C (en) 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2001074793A2 (en) 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
EP1320365A4 (en) 2000-09-21 2004-03-17 Bristol Myers Squibb Co SUBSTITUTED AZOLE DERIVATIVES AS AN INHIBITOR OF THE CORTICOTROPIN RELEASE FACTOR
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
ATE328874T1 (de) 2000-12-22 2006-06-15 Ortho Mcneil Pharm Inc Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
KR100979988B1 (ko) 2001-08-13 2010-09-03 얀센 파마슈티카 엔.브이. 2-아미노-4,5-삼치환 티아졸릴 유도체
WO2003039451A2 (en) * 2001-11-08 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Thiazole pyridazinones as adenosine antagonists
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
CA2480488A1 (en) 2002-05-07 2003-11-20 Neurosearch A/S Novel diazabicyclic biaryl derivatives
EP1624873A2 (en) 2003-04-28 2006-02-15 AB Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
MXPA05013075A (es) * 2003-06-03 2006-03-17 Novartis Ag Inhibidores de p-38 basados en heterociclo de 5 miembros.
EP1648876A1 (en) 2003-07-24 2006-04-26 Pharmagene Laboratories Ltd 5-ht sb 2b /sb receptor antagonists
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CA2580610C (en) * 2004-09-17 2013-07-09 Vertex Pharmaceuticals Incorporated Diaminotriazole compounds useful as protein kinase inhibitors
HRP20100715T1 (hr) 2004-10-21 2011-02-28 Vertex Pharmaceuticals Incorporated Triazoli korisni kao inhibitori protein kinaza
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
CN101263130B (zh) * 2005-09-13 2011-03-09 詹森药业有限公司 2-苯胺-4-芳基取代的噻唑衍生物
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
WO2009050186A1 (en) * 2007-10-18 2009-04-23 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
MX2010011358A (es) 2008-04-17 2010-11-10 Glaxo Group Ltd Indoles como moduladores del receptor nicotinico de acetilcolina subtipo alfa-71.
CL2009001125A1 (es) 2008-05-09 2011-02-11 Janssen Pharmaceutica Nv Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
US8791144B2 (en) * 2009-09-17 2014-07-29 Janssen Pharmaceutica Nv Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines
JO3078B1 (ar) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
EA022164B1 (ru) 2011-02-25 2015-11-30 Янссен Фармацевтика Нв (ПИРИДИН-4-ИЛ)БЕНЗИЛАМИДЫ КАК АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ АЛЬФА 7 nAChR

Also Published As

Publication number Publication date
EP2257535B1 (en) 2013-11-06
MX2010010127A (es) 2010-10-25
NZ587669A (en) 2011-07-29
AU2009226988B2 (en) 2013-05-23
CA2714662C (en) 2016-05-10
WO2009115547A8 (en) 2009-11-26
JP5383788B2 (ja) 2014-01-08
US20100324053A1 (en) 2010-12-23
MY152486A (en) 2014-10-15
EA201071094A1 (ru) 2011-02-28
KR101564303B1 (ko) 2015-11-06
ES2442932T3 (es) 2014-02-14
KR20100124258A (ko) 2010-11-26
UY31721A1 (es) 2009-09-30
CN102066343A (zh) 2011-05-18
IL208181A0 (en) 2010-12-30
US8778974B2 (en) 2014-07-15
EP2257535A1 (en) 2010-12-08
CN102066343B (zh) 2013-12-04
AU2009226988A1 (en) 2009-09-24
TW201000471A (en) 2010-01-01
PE20091618A1 (es) 2009-10-23
EA018186B1 (ru) 2013-06-28
ZA201006690B (en) 2012-03-28
TWI433847B (zh) 2014-04-11
JP2011515367A (ja) 2011-05-19
UA102681C2 (ru) 2013-08-12
IL208181A (en) 2013-10-31
CL2009000662A1 (es) 2010-02-05
CA2714662A1 (en) 2009-09-24
WO2009115547A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
AR070936A1 (es) 1,2,4 -triazoles trisustituidos
AR124662A2 (es) Formulaciones inmunosupresoras
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
MX344927B (es) Composición farmacéutica que contiene derivado de quinolina.
AR060537A1 (es) 1,2,4-triazoles trisustituidos
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
AR061923A1 (es) Compuestos derivados de benzofuran-piperidina
CO6351734A2 (es) Compuestos de amida utiles en terapia
AR059521A1 (es) Ariltienopirimidinas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
BR112012013511A2 (pt) derivados de difenil-pirazolopiridinas, sua preparação e seu uso como não moduladores do receptor nuclear
CO6150123A2 (es) Formulacion de aerosol que contiene derivados de benzoxazin-3onas
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR074341A1 (es) Derivados heterociclicos de isoindol, inhibidores de proteinasas bace, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de patologias relacionadas a deficiencias cognitivas, tales como alzheimer.
BR112012018958A2 (pt) sólido polimórfico ou forma solvatada do sal de cloridrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina, forma sólida processo para a preparação da forma de fase polimórfica i, da forma de fase polimórfica iii, da forma de fase polimórfica ii, da forma de fase polimórfica iv, do solvato de dioxano, do solvato de clorofórmio, uso da forma de fase polimórfica ii, forma de fase polimórfica iii, forma de fase polimórfica iv, solvato de dioxano ou solvato de clorofórmio, processo para a preparação da forma de fase i do sal de cloridrato de 4-[2-[[5-metil-1-(2-naftalenil_-1h-pirazol-3-il]oxi]etil]morfolina e composição farmacêutica
CO6170341A2 (es) Formulacion de aerosol que contiene derivados de benzoxazin-3onas
CR11636A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos
HRP20130327T1 (hr) Novi derivati dihidroindolona, postupak za njihovu pripravu i farmaceutski spojevi koji ih sadržavaju
AR065872A1 (es) Derivados de benzimidazol sustituidos con heterociclos,composiciones farmaceuticas que los contienen,proceso para prepararlos y sus usos en trastornos de ansiedad, trastornos depresivos y enfermedades de alzheimer, entre otros.
AR066242A1 (es) Tia(di)azoles como antagonistas del recpetor de dopamina 2 de disociacion rapida
AR062477A1 (es) Formulacion aerosol para la inhalacion de beta - agonistas

Legal Events

Date Code Title Description
FB Suspension of granting procedure